NCT01423838

Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder

Comparison of Oxybutynin and Solifenacin in the Treatment of Overactive Bladder: a Randomized Controlled Multicenter Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: Adana Numune Training and Research Hospital · Other Government
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Null hypothesis of the trial is that there is no difference between solifenacin and oxybutynin with respect to efficacy, side effects, patient satisfaction and quality of life measures in patients with overactive bladder.

Detailed description

In this two-month follow-up study, the patients with overactive bladder will be randomly assigned into two groups (solifenacin or oxybutynin in their usual doses) and will be assessed with respect to baseline characteristics and complaints before treatment. After initiation of the treatment at first and second months follow-up visits the patients will be reassessed with respect to compliance, satisfaction, degree of improvement, reasons for dropouts, number and severity of side effects.

Conditions

• Overactive Bladder

Interventions

Type	Name	Description
DRUG	Solifenacin	5 mg, oral, once in a day
DRUG	Oxybutynin	5 mg, oral, three times in a day

Timeline

• Start date: 2011-09-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2011-08-26
• Last updated: 2011-08-26

Locations

1 site across 1 country: Turkey (Türkiye)